CPT 82670: Total Estradiol, LC–MS/MS
Commercial payers pay $56 on average nationally for this procedure.
CPT code 82670 reports a laboratory assay for total estradiol measured on a blood specimen using methods such as liquid chromatography–tandem mass spectrometry (LC–MS/MS) to evaluate female and male hormonal status related to fertility and other endocrine conditions; service type: clinical laboratory test, typical site of service: clinical laboratory or hospital outpatient laboratory.
For related coverage guidance, see recent payer policy updates: Salivary Hormone Testing, Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing, Bone Turnover Markers Testing.
Customize your policy alerts
Sign up for cpt 82670 policy alerts
Get alerted when payer policies referencing 82670 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
For CPT 82670, BUCA’s average commercial rate sits at $55.6, representing the broad-market midpoint for commercial payers in this sample. Blue Cross Blue Shield is above BUCA with a mean of $75.4 and shows substantial dispersion between the 25th and 75th percentiles ($56.7 to $90.9), a P75–P25 spread of $34.2 indicating wider variability in negotiated prices. Aetna and Cigna have mean rates below BUCA at $33.9 and $28.7 respectively; Aetna’s interquartile spread is $14.4 (P75 $37.4 minus P25 $21.0), while Cigna’s spread is $24.7 (P75 $39.7 minus P25 $15.0). UnitedHealth Group’s mean of $25.0 pairs with the tightest interquartile range of $16.5 (P75 $27.9 minus P25 $12.4), suggesting more consistency.
Comparing dispersion across payers, Blue Cross Blue Shield displays the widest IQR at $34.2, reflecting the greatest variability among commercial contracts here. Cigna follows with a notable $24.7 spread, while UnitedHealth Group is the tightest at $16.5, and Aetna is relatively narrow at $16.4. BUCA’s quartiles ($39.3, $47.8, $67.0) give an IQR of $27.7, placing it between the wider BCBS and the tighter UnitedHealth Group and Aetna spreads, and illustrating that average commercial rates fall in the mid-range of observed payer variability.